1-6 of 6
Ling Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Joshua D. Thomas, Aleksandr V. Yurkovetskiy, Mao Yin, Natalya D. Bodyak, Shuyi Tang, Marina Protopopova, Eugene Kelleher, Brian Jones, Liping Yang, Daniel Custar, Kalli C. Catcott, Damon R. Demady, Scott D. Collins, Ling Xu, Charlie Bu, LiuLiang Qin, Elena Ter-Ovanesyan, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (4): 541–551.
https://doi.org/10.1158/1535-7163.MCT-23-0622
Published: 02 April 2024
View article titled, Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates
Open the PDF for Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios

Susan M. Clardy, Alex Uttard, Bingfan Du, Kalli C. Catcott, Kelly L. Lancaster, Elizabeth Ditty, Jack Sadowsky, Jeffrey Zurita, Naniye Malli, LiuLiang Qin, Stephen P. Bradley, Kenneth Avocetien, Tyler Carter, Dokyong Kim, Mark Nazzaro, Ling Xu, Thomas H. Pillow, Neelie T. Zacharias, Gail D. Lewis, Rebecca K. Rowntree, Radha Iyengar, David H. Lee, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (1): 84–91.
https://doi.org/10.1158/1535-7163.MCT-23-0262
Published: 03 January 2024
View article titled, Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Open the PDF for Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios in another window
Includes: Supplementary data
Journal Articles

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins, Patrick R. Conlon, Reddy Bollu, Kalli C. Catcott, Chen-Ni Chin, Anouk Dirksen, Bingfan Du, Jeremy R. Duvall, Stacy Higgins, Mariya V. Kozytska, Kamela Bellovoda, Chelsey Faircloth, David Lee, Fu Li, Liuliang Qin, Caitlin Routhier, Pamela Shaw, Cheri A. Stevenson, Jason Wang, Phonphimon Wongthida, Elena Ter-Ovanesyan, Elizabeth Ditty, Stephen P. Bradley, Ling Xu, Mao Yin, Alexandr V. Yurkovetskiy, Rebecca Mosher, Marc Damelin, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (9): 999–1012.
https://doi.org/10.1158/1535-7163.MCT-22-0786
Published: 05 September 2023
View article titled, Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Open the PDF for Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Kalli C. Catcott, Susan Clardy, Jack Sadowsky, Rebecca K. Rowntree, Naniye Malli Centibas, Ling Xu, Andy Polson, Kenneth Avocetien, Tyler Carter, Mark Nazzaro, Dokyong "DK" Kim, Thomas H. Pillow, Neelie Zacharias, Cong Wu, Jeffrey Zurita, Elizabeth Ditty, Stephen Bradley, Alex Uttard, Bingfan Du, William S. Sawyer, Doug Leipold, Gail Lewis Phillips, LiuLiang Qin, Kelly Slocum, Geoffrey Del Rosario, Ginny Li, Shang-Fan Yu, David Lee, Radha Iyengar, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P167.
https://doi.org/10.1158/1535-7163.TARG-21-P167
Published: 01 December 2021
View article titled, Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios
Journal Articles

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 885–895.
https://doi.org/10.1158/1535-7163.MCT-20-0166
Published: 01 May 2021
View article titled, Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Open the PDF for Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect in another window
Includes: Supplementary data
Journal Articles

The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry R. Gumerov, Venu R. Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, LiuLiang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Uttard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (5): 896–905.
https://doi.org/10.1158/1535-7163.MCT-20-0183
Published: 01 May 2021
View article titled, The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Open the PDF for The Dolaflexin-based Antibody–Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b in another window
Includes: Supplementary data